<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet type="text/xsl" href="https://blogs.mercola.com:443/utility/FeedStylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><xhtml:meta xmlns:xhtml="http://www.w3.org/1999/xhtml" name="robots" content="noindex" /><title>After Vioxx Recall, Other Drugs Under the Microscope</title><link>https://blogs.mercola.com:443/sites/vitalvotes/archive/2004/10/07/After-Vioxx-Recall-Other-Drugs-Under-the-Microscope.aspx</link><description>When I heard Vioxx was being pulled from the market late last week , it wasn't surprising to me to read Pfizer had stepped up production of Celebrex to meet the new patient demand. In a case of "being careful for what you wish for," two studies released</description><dc:language>en</dc:language><generator>CommunityServer 2008.5 SP1 (Debug Build: 31106.3070)</generator></channel></rss>